Geode Capital Management, LLC Heron Therapeutics, Inc. Transaction History

Geode Capital Management, LLC

$1.12 Trillion
Q2 2024

A detailed history of Geode Capital Management, LLC transactions in Heron Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 3,112,335 shares of HRTX stock, worth $5.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,112,335

Previous 2,796,119 11.31%

Holding current value

$5.6 Million

Previous $7.75 Million 40.65%

% of portfolio

0.0%

Previous 0.0%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	BUY	$2.32 - $3.86 $733,621 - $1.22 Million	316,216 Added 11.31%	3,112,335 $10.9 Million
Q1 2024 May 13, 2024	BUY	$1.71 - $3.06 $293,170 - $524,621	171,445 Added 6.53%	2,796,119 $7.75 Million
Q4 2023 Feb 13, 2024	BUY	$0.54 - $1.82 $123,937 - $417,713	229,513 Added 9.58%	2,624,674 $4.46 Million
Q3 2023 Nov 13, 2023	BUY	$0.97 - $1.8 $330,512 - $613,323	340,735 Added 16.59%	2,395,161 $2.47 Million
Q2 2023 Aug 11, 2023	BUY	$1.11 - $2.88 $88,213 - $228,879	79,472 Added 4.02%	2,054,426 $2.38 Million
Q1 2023 May 15, 2023	BUY	$1.51 - $3.25 $24,933 - $53,664	16,512 Added 0.84%	1,974,954 $2.98 Million
Q4 2022 Feb 13, 2023	BUY	$2.25 - $4.67 $297,321 - $617,107	132,143 Added 7.24%	1,958,442 $4.9 Million
Q3 2022 Nov 14, 2022	BUY	$2.66 - $5.37 $36,348 - $73,381	13,665 Added 0.75%	1,826,299 $7.71 Million
Q2 2022 Aug 12, 2022	BUY	$2.3 - $6.29 $387,030 - $1.06 Million	168,274 Added 10.23%	1,812,634 $5.06 Million
Q1 2022 May 13, 2022	SELL	$4.63 - $9.94 $311,358 - $668,445	-67,248 Reduced 3.93%	1,644,360 $9.41 Million
Q4 2021 Feb 11, 2022	BUY	$8.35 - $12.6 $828,595 - $1.25 Million	99,233 Added 6.15%	1,711,608 $15.6 Million
Q3 2021 Nov 12, 2021	BUY	$10.13 - $15.0 $232,817 - $344,745	22,983 Added 1.45%	1,612,375 $17.2 Million
Q2 2021 Aug 13, 2021	BUY	$13.27 - $18.48 $1.97 Million - $2.74 Million	148,247 Added 10.29%	1,589,392 $24.7 Million
Q1 2021 May 12, 2021	BUY	$14.49 - $20.72 $1.98 Million - $2.83 Million	136,474 Added 10.46%	1,441,145 $23.4 Million
Q4 2020 Feb 12, 2021	BUY	$14.61 - $22.14 $692,236 - $1.05 Million	47,381 Added 3.77%	1,304,671 $27.6 Million
Q3 2020 Nov 13, 2020	SELL	$13.67 - $17.77 $148,948 - $193,621	-10,896 Reduced 0.86%	1,257,290 $18.6 Million
Q2 2020 Aug 13, 2020	BUY	$10.89 - $21.47 $660,750 - $1.3 Million	60,675 Added 5.02%	1,268,186 $18.7 Million
Q1 2020 May 14, 2020	BUY	$10.23 - $24.56 $769,817 - $1.85 Million	75,251 Added 6.65%	1,207,511 $14.2 Million
Q4 2019 Feb 13, 2020	BUY	$17.42 - $26.61 $3.66 Million - $5.59 Million	210,035 Added 22.77%	1,132,260 $26.6 Million
Q3 2019 Nov 12, 2019	BUY	$16.36 - $21.39 $411,372 - $537,851	25,145 Added 2.8%	922,225 $17.1 Million
Q2 2019 Aug 14, 2019	BUY	$16.93 - $26.22 $1.39 Million - $2.15 Million	81,852 Added 10.04%	897,080 $16.7 Million
Q1 2019 May 14, 2019	BUY	$23.15 - $28.34 $1.48 Million - $1.81 Million	63,978 Added 8.52%	815,228 $19.9 Million
Q4 2018 Feb 13, 2019	BUY	$22.03 - $32.01 $582,230 - $845,992	26,429 Added 3.65%	751,250 $19.5 Million
Q3 2018 Nov 13, 2018	BUY	$30.0 - $40.85 $2.32 Million - $3.15 Million	77,210 Added 11.92%	724,821 $22.9 Million
Q2 2018 Aug 14, 2018	BUY	$26.4 - $42.0 $4.54 Million - $7.22 Million	171,911 Added 36.14%	647,611 $25.2 Million
Q1 2018 May 15, 2018	BUY	$18.43 - $28.8 $1.44 Million - $2.25 Million	78,244 Added 19.69%	475,700 $13.1 Million
Q4 2017 Feb 13, 2018	BUY	$14.8 - $18.85 $35,668 - $45,428	2,410 Added 0.61%	397,456 $7.19 Million
Q3 2017 Nov 14, 2017	BUY	$14.65 - $16.85 $123,353 - $141,877	8,420 Added 2.18%	395,046 $6.38 Million
Q2 2017 Aug 14, 2017	BUY	N/A	386,626	386,626 $5.35 Million

Others Institutions Holding HRTX

# of Institutions

198

Shares Held

129M

Call Options Held

94.7K

Put Options Held

148K

View Full List

About HERON THERAPEUTICS, INC.

Ticker HRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 118,774,000
Market Cap $214M
Description
Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single a...

More about HRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Account

Geode Capital Management, LLC Heron Therapeutics, Inc. Transaction History